Investigating how tumor cells affect immune cells in lung cancer
CSF1 Receptor-Mediated Tumor Microenvironment in Lung Cancer
['FUNDING_OTHER'] · JESSE BROWN VA MEDICAL CENTER · NIH-11075194
This study is looking at how certain immune cells in lung cancer are affected by a substance made by tumors, with the goal of finding new ways to improve cancer treatments that help your immune system fight the disease.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JESSE BROWN VA MEDICAL CENTER (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11075194 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of specific immune cells, particularly macrophages and dendritic cells, in the tumor microenvironment of lung cancer. The team of immunologists and oncologists aims to explore how tumor-produced Colony Stimulating Factor 1 (CSF1) alters these immune cells to promote cancer progression. By examining the mechanisms of CSF1 and its effects on myeloid cells, the research seeks to identify new therapeutic strategies that could enhance cancer immunotherapy. Patients may benefit from insights that could lead to more effective treatments targeting the tumor microenvironment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung cancer who may be eligible for immunotherapy.
Not a fit: Patients with non-cancerous conditions or those not diagnosed with lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy strategies that improve treatment outcomes for lung cancer patients.
How similar studies have performed: Other research has shown promise in targeting tumor microenvironments for cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
CHICAGO, UNITED STATES
- JESSE BROWN VA MEDICAL CENTER — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PARK, GYE YOUNG — JESSE BROWN VA MEDICAL CENTER
- Study coordinator: PARK, GYE YOUNG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy